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Citrullinated Inhibitor of DNA Binding 1 Is a Novel 
Autoantigen in Rheumatoid Arthritis
Ray A. Ohara,1 Gautam Edhayan,1 Stephanie M. Rasmussen,1 Takeo Isozaki,2 Henriette A. Remmer,1  
Thomas M. Lanigan,1 Phillip L. Campbell,1 Andrew G. Urquhart,3 Jeffrey N. Lawton,3 Kevin C. Chung,3   
David A. Fox,1 and Jeffrey H. Ruth1
Objective. To explore the intrinsic role of inhibitor of DNA binding 1 (ID- 1) in rheumatoid arthritis (RA) fibroblast- 
like synoviocytes (FLS) and to investigate whether ID- 1 is citrullinated and autoantigenic in RA.
Methods. RA patient serum ID- 1 levels were measured before and after infliximab treatment. RA FLS were trans-
fected with a clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR- associated protein 9 con-
struct targeting ID- 1 to examine the effects of ID- 1 deletion. RA synovial fluid (SF) and homogenized synovial tissue 
(ST) were immunoprecipitated for ID- 1 and measured for citrullinated residues using an enzyme- linked immuno-
sorbent assay and Western blotting. Liquid chromatography tandem mass spectrometry (LC- MS/MS) was performed 
on in vitro–citrullinated recombinant human ID- 1 (cit–ID- 1) to localize the sites of citrullination. Normal and RA sera 
and SF were analyzed by immunodot blotting for anti–citrullinated protein antibodies (ACPAs) to cit–ID- 1.
Results. RA patient serum ID- 1 levels positively correlated with several disease parameters and were reduced 
after infliximab treatment. RA FLS displayed reduced growth and a robust increase in interleukin- 6 (IL- 6) and IL- 8 
production upon deletion of ID- 1. ID- 1 immunodepletion significantly reduced the levels of citrullinated residues in RA 
SF, and citrullinated ID- 1 was detected in homogenized RA ST (n = 5 samples; P < 0.05). Immunodot blot analyses 
revealed ACPAs to cit–ID- 1 but not to native ID- 1, in RA peripheral blood (PB) sera (n = 30 samples; P < 0.001) and SF 
(n = 18 samples; P < 0.05) but not in normal PB sera. Following analyses of LC- MS/MS results for citrullination sites 
and corresponding reactivity in immunodot assays, we determined the critical arginines in ID- 1 for autoantigenicity: 
R33, R52, and R121.
Conclusion. Novel roles of ID- 1 in RA include regulation of FLS proliferation and cytokine secretion as well as 
autoantigenicity following citrullination.
INTRODUCTION
Inhibitor of DNA binding 1 (ID- 1) is a nuclear transcrip-
tion factor containing a helix- loop- helix domain that it uti-
lizes to regulate cell growth and differentiation via selective 
binding and sequestering of distinct transcription factors. By 
this method, ID- 1 controls transcriptional activation of target 
genes. ID- 1 is also known to be actively transcribed in cells 
exhibiting hyperproliferative responses and is regarded as a 
marker of cellular self- renewal. Rheumatoid arthritis (RA) syno-
vial fluid (SF) contains abundant amounts of ID- 1, and the pri-
mary source is activated RA fibroblast- like synoviocytes (FLS). 
Once released, ID- 1 acts as a potent inducer of angiogene-
sis and also exhibits endothelial progenitor cell chemotactic 
activity (1), suggesting that ID- 1 may contribute to angiogen-
esis and vasculogenesis by independent mechanisms. ID- 1 is 
packaged into exosomes, which are released from FLS and 
potentially delivered to other inflammatory cells within RA 
synovium (2). Although the concept of a secreted nuclear pro-
tein may be unconventional, a similar phenomenon occurs in 
the inflamed joint with DEK, a nuclear protein that functions as 
a regulator of transcription involved in chromatin architecture 
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and messenger RNA processing. DEK is secreted by mac-
rophages, found in exosomes, can be detected in the SF of 
juvenile arthritis patients, and is both an autoantigen and a 
potent neutrophil chemotactic factor (3,4).
In the current study, we investigated 3 potential key roles for 
ID- 1 in RA: first, as a secreted nuclear protein whose levels corre-
late with several disease parameters; second, as a regulator of cell 
proliferation and inflammatory cytokine production by FLS; and 
third, as a citrullinated autoantigen. We assessed the roles of ID- 1 
in FLS by use of clustered regularly interspaced short palindromic 
repeat (CRISPR)/CRISPR- associated protein 9 (Cas9) targeting 
of ID- 1. Immunoassays were used to measure citrullinated ID- 1 
(cit–ID- 1) in synovial tissue (ST). Mass spectrometry was used 
to define the specific arginines within ID- 1 that are converted to 
citrulline as well as the identity of specific citrulline residues that 
render ID- 1 autoantigenic. The results suggest multidimensional 
contributions of ID- 1 and cit–ID- 1 to the pathogenesis of RA.
PATIENTS AND METHODS
Patient samples. Data were collected from a cohort of 27 
RA patients (2009–2012), who met the 1987 American College of 
Rheumatology (ACR) classification criteria (5) for RA. Twenty- seven 
serum samples (median patient age 49 years [range 21–76]) were 
collected from the patients before the initial treatment with inflix-
imab. All RA patients were receiving methotrexate and 14 were 
receiving additional disease- modifying antirheumatic drugs (sul-
fasalazine or bucillamine). Fourteen age- and sex- matched healthy 
volunteers (median age 42.5 years [range 29–55]) were recruited 
as controls. All specimens were obtained with written informed 
consent and collected following approval from the Showa Univer-
sity Institutional Review Board (IRB). SF samples were obtained 
from RA patients during arthrocentesis and stored at −80°C in 
aliquots after centrifugation to remove SF cells. ST samples were 
obtained from RA patients undergoing total joint replacement and 
were snap- frozen (liquid nitrogen) in 10% DMSO in fetal bovine 
serum and stored at −80°C. These samples were obtained, with 
IRB approval, from RA patients who met the ACR criteria for RA.
Enzyme- linked immunosorbent assay. Patient sam-
ples and normal control samples were analyzed using enzyme- 
linked immunosorbent assay (ELISA) kits for human ID- 1 
(MyBioSource) and rheumatoid factor (RF; Alpha Diagnostic 
International). For the ID- 1 targeting experiments, cell culture 
supernatants were mea sured with ELISA kits for human inter-
leukin- 13 (IL- 13), epithelial neutrophil–activating peptide 78 
(ENA- 78/CXCL5), IL- 6, and IL- 8 (R&D Systems). (For detection 
of citrulline residues by ELISA [cit-ELISA], see Supplementary 
Methods, on the Arthritis & Rheumatology web site at http://
onlin elibr ary.wiley.com/doi/10.1002/art.40886/ abstract.)
CRISPR/Cas9 targeting of ID- 1. CRISPR U6gRNA- pCMV- 
Cas9- 2A–red fluorescent protein (RFP) plasmid (Sigma- Aldrich) 
containing the guide RNA (gRNA) 5′- GAATCATGAAAGTCG 
CCAGTGG- 3′ was designed to target the human ID- 1 gene. 
CRISPR human EMX1- s4 positive control plasmid (no. 
CRISPR11- 1EA; Sigma- Aldrich) and CRISPR plasmid target-
ing an irrelevant gene (e.g., THBS1) were used as controls. All 
transfections were performed by electroporation using Amaxa 
Nucleofector Technology (Lonza). Transfected cells were sorted 
for fluorescent marker (RFP or green fluorescent protein [GFP]) 
via fluorescence- activated cell sorting (FACS) and analyzed for 
CRISPR/Cas9 activity by Tracking of Indels by Decomposition 
(TIDE) using Desktop Genetics web tool (6). To verify ID- 1 deple-
tion, transfected cells were lysed in radioimmunoprecipitation 
assay (RIPA) buffer supplemented with EDTA- free protease inhib-
itor cocktail (ThermoFisher Scientific) and analyzed by Western 
blotting. For assays of cell proliferation and cytokine expressions, 
sorted cells were plated in 96- well plates (6,000–10,000 cells/
well) in complete cell culture medium and imaged hourly for 120 
hours using the IncuCyte S3 Live Cell Analysis System (Essen 
Biosciences). Cell culture supernatants were collected at 24 
hours postseeding for analysis by ELISA.
Immunoprecipitation. For ID- 1 pulldown experiments, 
a Direct Immunoprecipitation kit (ThermoFisher Scientific) was 
used with polyclonal rabbit anti–ID- 1 antibodies (nos. ab170511 
and ab192303; Abcam) or with rabbit IgG isotype control (Ther-
moFisher Scientific). RA ST (~0.5 cm3) homogenates were pre-
pared in ice- cold RIPA buffer supplemented with EDTA- free 
protease inhibitor cocktail using an electric homogenizer and were 
centrifuged and filtered (45 μm) to collect the supernatant. For all 
immunoprecipitation experiments, manufacturers’ kit protocols 
were followed. Samples were eluted with low- pH elution buffer 
supplied in the kit and prepared in Laemmli sample buffer for West-
ern blotting; flowthroughs were retained for ELISA. All sera, SF, and 
ST homogenates were incubated with polyclonal goat anti- human 
IgM (μ- chain specific)–conjugated Agarose (Sigma- Aldrich) at 4°C 
overnight for removal of RF prior to all immunoassays.
Citrullination of recombinant human ID- 1 protein. 
Recombinant human ID- 1 protein (rhID- 1) (OriGene Technolo-
gies) was citrullinated in vitro using recombinant human pepti-
dylarginine deiminase 4 (rhPAD4) enzyme (Cayman Chemical) or 
rabbit PAD enzyme (Sigma- Aldrich) as previously described (7). 
The preparation of noncitrullinated ID- 1 (noncit–ID- 1) was per-
formed similarly, with cell culture–grade water (Sigma- Aldrich) in 
place of PAD enzymes.
Western blotting. Citrullinated and noncitrullinated 
proteins (100 ng each) and IP- eluted samples from RA ST 
homogenates (30 μl) were prepared in Laemmli sample buffer 
and were resolved by sodium dodecyl sulfate–polyacrylamide 
gel electrophoresis (SDS- PAGE) before transfer to nitrocellulose 
membranes (NCMs) using a semi- dry transfer cell (Bio- Rad). 
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Blots were washed with 0.05% Tween 20 in Tris buffered saline 
(TBST) between all subsequent steps. After blocking in 5% non-
fat dry milk in TBST, the blots were probed with monoclonal rab-
bit anti–ID- 1 (1:1,000 dilution) (no. TA310605, clone EPR7098; 
OriGene Technologies) and then probed with horseradish per-
oxidase–linked anti- rabbit IgG (1:1,000 dilution) (no. 7074; Cell 
Signaling Technology). SuperSignal West Dura Extended Dura-
tion Substrate (ThermoFisher Scientific) was used for detection 
prior to image acquisition with an Amersham Imager 600 (GE 
Healthcare Life Sciences). (For detection of citrulline residues 
by Western blotting, see Supplementary Methods, available at 
http://onlin elibr ary.wiley.com/doi/10.1002/art.40886/ abstract.)
Figure 1. Effect of infliximab treatment on serum inhibitor of DNA binding 1 (ID- 1) levels in patients with rheumatoid arthritis (RA), and clinical 
correlations. A, ID- 1 levels were elevated in RA serum (n = 27) compared to those in serum from age- and sex- matched normal controls (n = 14). B, 
Serum ID- 1 levels in patients were decreased at the 12- week time point following infliximab treatment. The red broken line indicates the detection 
limit of the ID- 1 enzyme- linked immunosorbent assay (7.81 pg/ml). Bars in A and B represent the mean ± SEM. C, ID- 1 levels and clinical parameters 
were decreased following treatment with infliximab. Each colored line represents a single patient. D, Baseline serum ID- 1 levels correlated with various 
clinical and laboratory parameters. E, Change in ID- 1 levels from baseline to posttreatment correlated with change in the Simplified Disease Activity 
Index (SDAI), showing improved SDAI scores with decreased ID- 1 levels (n = 24). * = P < 0.05; ** = P < 0.01. MMP- 3 = matrix metalloproteinase 3; 
ESR = erythrocyte sedimentation rate; DAS28 = Disease Activity Score in 28 joints; CRP = C- reactive protein; CDAI = Clinical Disease Activity Index. 
Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40886/abstract.
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In- gel digestion and liquid chromatography tan-
dem mass spectrometry (LC- MS/MS). LC- MS/MS was 
performed by Proteomics and Peptide Synthesis Core at the 
University of Michigan (Supplementary Methods, http://onlin elibr 
ary.wiley.com/doi/10.1002/art.40886/ abstract).
Immunodot blotting. Samples were dotted onto 
NCMs at 10 ng/dot and blocked in 5% goat serum (Sigma- 
Aldrich) in TBS. Blots were incubated in either samples (RA 
SF or PB serum, normal PB serum; 1:10,000 dilution), nor-
mal human IgG control (1 μg/ml) (no. 1001A; R&D Systems), 
or control antibodies, including monoclonal mouse anti–ID- 1 
(no. ab66495, clone 2456C1a; Abcam) and polyclonal rab-
bit anti- PAD4 (1 μg/mL) (no. ab50247; Abcam), then probed 
with peroxidase AffiniPure goat anti- human IgG (1 μg/ml, dilu-
tion 1:5,000) (no. 109035003; ImmunoResearch). To verify 
specificity for cit–ID- 1 reactivity of RA specimens, additional 
control blots were included on the same NCMs using various 
proteins including noncit–ID- 1, bovine serum albumin (BSA), 
cit- BSA, ENA- 78, cit–ENA- 78, and rhPAD4. Densitometry 
analysis was performed using ImageJ (National Institutes of 
Health).
Figure 2. Transfection of RA fibroblast- like synoviocytes (FLS) with clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR- 
associated protein 9 (Cas9) plasmid with guide RNA targeting the ID- 1 gene. A, Fluorescence- activated cell sorting of RA FLS that were 
transfected with ID- 1 CRISPR/Cas9 plasmid or control THBS1 CRISPR/Cas9 plasmid is shown. B, RA FLS transfected with ID- 1 CRISPR/Cas9 
plasmid (n = 9) or THBS1 control plasmid (n = 19) were assayed for cell proliferation using the IncuCyte S3 Live- Cell Analysis System. C, Due 
to imperfect repair by Cas9 nuclease, DNA in the cell pool contained a mixture of indels, yielding a composite sequence trace after the break 
site (black dashed line). An overview of Tracking of Indels by Decomposition algorithm and output is shown, consisting of visualization of aberrant 
sequence signal in controls (black) and treated samples (green). Cas9 nuclease cut the genome, and the cell repaired the damage caused by 
nonhomologous end–joining resulting in aberrant sequences. D, RA FLS transfected with sham control (n = 17 or more per experiment), green 
fluorescent protein (GFP) control (n = 5 per experiment), or ID- 1 CRISPR/Cas9 plasmid (n = 5 or more per experiment) were sorted and cultured 
for 24 hours for cytokine expression analysis using enzyme- linked immunosorbent assays. Values are the mean ± SEM. * = P < 0.05. IL- 13 = 
interleukin- 13 (see Figure 1 for other definitions).
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Statistical analysis. GraphPad Prism was used for all 
statistical analyses. Group differences in serum ID- 1 levels were 
evaluated by unpaired nonparametric Mann- Whitney U test or 
paired nonparametric Wilcoxon signed rank test. Correlations 
between serum ID- 1 levels and clinical parameters were as-
sessed by nonparametric Spearman’s rank correlation. Results 
of cell proliferation assay and ELISAs used to detect cytokine 
expression were analyzed by unpaired parametric t- test. Lev-
els of total citrullinated antigens in RA SF depleted of ID- 1 were 
evaluated by paired nonparametric Wilcoxon signed rank test. 
Results are expressed as the mean ± SEM. Two- tailed P values 
less than 0.05 were considered significant.
RESULTS
Correlations between serum ID- 1 levels and dis-
ease parameters, and effect of infliximab treatment. 
Serum ID- 1 levels were measured in a Japanese cohort of 27 
RA patients before and after infliximab treatment. We found that 
serum ID- 1 levels were significantly elevated compared to those 
in age- and sex- matched normal controls (Figure  1A). Serum 
ID- 1 levels before and 12 weeks after initiation of infliximab were 
compared. We observed a significant decrease in ID- 1 levels 
after infliximab treatment (Figure 1B). Additionally, several clini-
cal and laboratory parameters were measured, including matrix 
metallopeptidase 3 (MMP- 3) level, erythrocyte sedimentation 
rate (ESR), the Disease Activity Score in 28 joints using ESR 
(DAS28- ESR) (8), and the Simple Disease Activity Index (SDAI) 
(9), with significant improvements observed after infliximab treat-
ment (Figure 1C). Next, baseline serum ID- 1 levels were analyzed 
for correlation with disease parameters including RF, ESR, C- re-
active protein (CRP) level, MMP- 3 level, SDAI, Clinical Disease 
Activity Index (CDAI) (9), DAS28 using CRP level (DAS28- CRP), 
and DAS28- ESR. We found positive correlations between ID- 1 
levels and all of these parameters except RF (Figure 1D). Anal-
ysis using the change in SDAI score of responders and nonre-
sponders after infliximab treatment showed that the serum ID- 1 
level correlated significantly with reduction in disease activity in 
the responders (24 of 27 patients) (Figure 1E).
In vitro targeting of ID- 1 in RA FLS with the CRISPR/
Cas9 system. We have previously shown that ID- 1 is up- 
regulated in RA synovium and that soluble ID- 1 exhibits inflam-
matory and angiogenic properties (1,2). To examine the effects 
of ID- 1 targeting in RA FLS by CRISPR/Cas9, cell proliferation 
assays were performed using the IncuCyte S3 Live Cell Analysis 
System. Results of ID- 1 gene targeting were compared to those 
from the targeting of an irrelevant gene, THBS1. We achieved a 
maximum efficiency of 24.8% (Figure  2A), which was sufficient 
(due to an ample starting number of cells) for downstream experi-
ments that used only the sorted RFP- positive cells. We found sig-
nificant reductions in FLS growth beginning 13 hours after plating 
in culture (Figure 2B). To fully verify active and accurate genome 
editing by Cas9, transfected cells were sorted via FACS, and 
Figure 3. Immunodepletion of inhibitor of DNA binding 1 (ID- 1) and detection of citrullinated ID- 1 (cit–ID- 1) in rheumatoid arthritis (RA) synovial 
fluid (SF) and synovial tissue (ST). A, Immunodepletion of ID- 1 in RA SF (n = 5) using anti–ID- 1 polyclonal antibody (pAb) was verified by enzyme- 
linked immunosorbent assay. B, Levels of total citrullinated antigens were measured in ID- 1–depleted RA SF. Significant reduction in total 
citrullinated antigens after ID- 1 depletion suggested that ID- 1 is present in citrullinated forms in RA SF. C, Total citrullinated protein concentration 
in isotype control versus in anti–ID- 1 antibody–treated RA SF was measured. Bars show the mean ± SEM. D, Detection of citrullinated forms 
of ID- 1 in RA ST is shown. Immunoprecipitation (IP) was performed on RA ST homogenates using anti–ID- 1 antibody, and blots were probed 
for ID- 1 or total citrullinated antigens. Cit–ID- 1 was detected in 2 of 3 RA ST homogenates. * = P < 0.05. WB = Western blotting; AMC = 
antimodified citrulline. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40886/
abstract.
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genomic DNA was isolated and sequenced. We then analyzed for 
aberrant sequences at the target site caused by indels of nonho-
mologous end–joining (NHEJ) using TIDE analysis (Figure 2C). We 
observed aberrant sequences and corresponding indel frequen-
cies with an overall efficiency of 4.4% at the P value threshold of 
0.001 with an R2 of 0.99. To verify ID- 1 depletion, Western blot 
analysis was performed on the sorted cells (Supplementary Figure 
1, http://onlin elibr ary.wiley.com/doi/10.1002/art.40886/ abstract).
Decreased cellular proliferation and increased IL- 6 
and IL- 8 production resulting from deletion of ID- 1 in 
RA FLS. Sorted cells were cultured for 24 hours following over-
night serum starvation, and supernatants were analyzed for 
cytokine expression (IL- 13, ENA- 78/CXCL5, IL- 6, and IL- 8) by 
ELISA (Figure 2D). RA FLS transfected with GFP control plasmid 
served as experimental control. We found significantly increased 
production of IL- 6 and IL- 8 compared to the controls, with no 
significant changes in IL- 13 or ENA- 78/CXCL5. RA FLS do not 
secrete appreciable amounts of IL- 13, which was measured as a 
control cytokine in these experiments. RA FLS do spontaneously 
secrete ENA- 78/CXCL5, as well as IL- 6 and IL- 8, but no sub-
stantial changes in ENA- 78/CXCL5 levels were seen, indicating 
that the increases in IL- 6 and IL- 8 are specific effects of CRISPR/
Cas9 targeting of the ID- 1 gene.
Detection of cit–ID- 1 in RA SF and ST. In the 2- step 
strategy to discover cit–ID- 1, we first performed immunoprecip-
itation on RA SF using polyclonal antibodies independently to pull 
out both native and citrullinated forms of ID- 1. Before proceeding 
to the second step, effective depletion of ID- 1 from RA SF was 
verified using ELISA (Figure 3A). We then conducted an indirect 
ELISA on the depleted RA SF to detect total citrullinated anti-
gens using antimodified citrulline (AMC) antibody (Supplementary 
Methods, http://onlin elibr ary.wiley.com/doi/10.1002/art.40886/ 
abstract). Depletion of ID- 1 significantly reduced the level of the 
total citrullinated antigens in RA SF (Figure 3B). This suggests that 
the anti–ID- 1 antibody that was used recognized both forms of ID- 
1, and that cit–ID- 1 is present in RA SF. The data also showed that 
total citrullinated protein concentration was significantly higher in 
isotype controls versus anti–ID- 1 antibody–treated SF samples 
(Figure 3C). Next, ID- 1 immunoprecipitated from RA ST homoge-
nates (using the same anti–ID- 1 antibody) was analyzed by West-
ern blotting using an AMC antibody (Supplementary Methods, 
http://onlin elibr ary.wiley.com/doi/10.1002/art.40886/ abstract). 
We detected a single prominent band (or complex of adjacent 
bands) when probing either for ID- 1 directly with an anti–ID- 1 anti-
body or for cit–ID- 1 indirectly with an AMC antibody. Two of the 3 
samples tested contained citrullinated forms of ID- 1 (Figure 3D).
In vitro citrullination of rhID- 1 protein. We incubated 
rhID- 1 with rhPAD4 at various enzyme:substrate molar ratios in 
appropriate reaction buffer. To control for the potential confound-
ing effects of conditions and reaction buffer, parallel aliquots of 
rhID- 1 were subjected to the same conditions except rhPAD4 was 
replaced with sterile water. To verify whether rhID- 1 was citrul-
linated, we performed Western blotting and found that cit–ID- 1 
was recognized by the AMC antibody, while noncit–ID- 1 was not 
recognized, as expected (Figure 4A). As a control, we also probed 
the samples using an anti–ID- 1 antibody and confirmed that non-
cit–ID- 1 was recognized (Figure 4A); cit–ID- 1 was also recognized 
with this antibody, suggesting that citrullination did not alter its 
Figure 4. In vitro citrullination of recombinant human ID- 1 (rhID- 1) 
by recombinant human anti–peptidylarginine deiminase 4 (rhPAD4). 
A, Citrullination of rhID- 1 by rhPAD4 was verified by Western blotting. 
Representative blots of cit–ID- 1 (lane 1) and noncit–ID- 1 (lane 2) were 
probed with anti–ID- 1 or AMC antibodies. Cit–ID- 1 exhibited multiple 
forms corresponding to the degree of modification and extended 
noticeably higher than noncit–ID- 1, likely due to the increased 
hydrophobicity and the change in charge from the citrullination 
reaction. B, Citrullination of rhID- 1 by rhPAD4 was verified via enzyme- 
linked immunosorbent assay (ELISA). Standard indirect ELISA 
protocol was modified to incorporate an acidic modification step for 
the AMC antibody as described. Cit–ID- 1 and noncit–ID- 1 can be 
distinguished by AMC antibody. Cit–ID- 1 produced an OD equivalent 
to ~300 ng/ml of citrullinated bovine serum albumin (BSA), which was 
used as a relative standard due to its abundant modifiable arginines. 
Values are the mean ± SEM. See Figure 3 for other definitions. Color 
figure can be viewed in the online issue, which is available at http://
onlinelibrary.wiley.com/doi/10.1002/art.40886/abstract.
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epitope and that both forms can be recognized by a single anti-
body. In addition, we performed ELISAs using the AMC antibody 
on cit–ID- 1 for further confirmation of citrullination. We observed a 
markedly higher absorbance in the cit–ID- 1 sample as compared 
to that of the noncit–ID- 1 sample (Figure 4B). Citrullinated BSA 
(cit- BSA) was used as a positive control for citrullination and as a 
relative standard for this ELISA.
LC- MS/MS identification of specific citrullines in in 
vitro–citrullinated rhID- 1. Human ID- 1 contains 10 arginines 
(Figure 5A), all of which are potential candidates for citrullination by 
PAD enzymes. We found that cit–ID- 1 extends visibly higher than 
noncit–ID- 1 on a gel (Figure 5B), likely due to the increase in hydro-
phobicity and the change in charge from positive to neutral due to 
the citrullination reaction. Subsequently, the samples were analyzed 
by LC- MS/MS to detect the site(s) of citrullination based on the 
tandem MS fragmentation pattern and the expected neutral loss 
of isocyanic acid that is diagnostic for citrullination in MS (10). We 
found multiple citrullinated arginines, varying in number depending 
on the batch of rhID- 1 and the experimental conditions of in vitro cit-
rullination. Arginine R121 was consistently citrullinated by rhPAD4, 
as shown in a representative spectrum (Figure  5C). Interestingly, 
LC-MS/MS analysis identified native citrulline residues in the noncit–
ID- 1 samples, which were expected from the production of rhID- 1 
in HEK 293T cells. However, with Western blot analysis using an 
AMC antibody these citrulline residues were not recognized (Fig-
ure 4A), suggesting that LC-MS/MS analysis is a more sensitive 
technique to identify low- level constitutive citrullination.
Measurement of ACPA reactivity with cit–ID- 1 in 
normal and RA PB sera and RA SF. We found positive ACPA 
reactivity against cit–ID- 1 but not against noncit–ID- 1, in RA PB 
sera and SF (Figure 6A). All antigens, including control antigens 
(noncit–ID- 1, BSA, cit- BSA, ENA- 78, citENA- 78, as well as 
rhPAD4 [data not shown]), were dotted in triplicate on the same 
blot and probed together in the same patient sample to ensure 
citrulline- specific binding by the ACPAs. All control blots showed 
no significant evidence of antibody binding but did show pos-
itivity for cit–ID- 1 (Supplementary Figure 2, http://onlin elibr ary.
wiley.com/doi/10.1002/art.40886/ abstract). Normal sera were 
used as controls, and no reactivity was observed. To control for 
nonspecific serum antibody binding, human IgG was used at a 
Figure 5. Liquid chromatography tandem mass spectrometry analysis (LC- MS/MS) of in vitro citrullinated recombinant human ID- 1 (rhID- 1). 
A, Sequence of human ID- 1 isoform 1 is shown. Human ID- 1 contains 10 arginines (R, highlighted red). RhID- 1 was citrullinated in vitro by 
recombinant human anti–peptidylarginine deiminase 4 (rhPAD4) and analyzed via LC- MS/MS. B, Cit–ID- 1 and noncit–ID- 1 were run on sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis and stained with “blue- silver” Coomassie for in- gel digestion prior to LC- MS/MS. C, The 
annotated mass spectrum of tryptic peptide confirmed citrullination of R121 in rhID- 1. All detected ions of the peptide are shown in black in 
the sequence and are annotated in the spectrum. The red r denotes citrulline. Ions highlighted in red in the spectrum show the neutral loss of 
isocyanic acid (HNCO; ~43 daltons), diagnostic marker ions for citrullination. See Figure 3 for other definitions. Color figure can be viewed in the 
online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40886/abstract.
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relatively high dilution (1 μg/ml). Furthermore, all additional con-
trol antibodies were negative (data not shown). By densitometry 
analysis of immunodot blotting, we found that 40% of RA sera 
recognized cit–ID- 1 versus no control sera. SF from 16.7% of RA 
patients tested positive for anti–cit–ID- 1 (Figure 6B).
Identification of the critical arginines conferring 
autoantigenicity to cit–ID- 1. Immunodot blot analysis for 
ACPA reactivity showed that cit–ID- 1 displayed unique autoan-
tigenicity and autoantibody reactivity, depending on the citrul-
lination pattern. Specifically, samples that showed reactivity 
with batches 1 and 2 did not shown any reactivity with batch 3, 
likely due to the lack of key epitopes. Thus, a batch was desig-
nated ACPA positive if it showed reactivity with any of the limited 
patient samples. We did not observe any ACPA binding to the 
baseline- modified arginines that were present in rhID- 1 obtained 
from the vendor. Using a series of LC- MS/MS and immunodot 
blot analyses, we identified key arginines in rhID- 1 that may be 
autoantigenic targets for ACPA development in RA. Of the 10 
available arginines in rhID- 1, the critical arginines for ACPA reac-
tivity were located at positions R33, R52, and R121 (Figure 6C). 
To further study the role of these arginines, citrullinated peptides 
(12 amino acids in length) spanning these regions were tested 
but were negative for ACPA binding (data not shown). Moreo-
ver, denaturing of cit–ID- 1 before immunodot blotting negated 
its reactivity (Figure 6A). Thus, the critical arginines at R33, R52, 
and R121 may control conformational epitopes that render cit–
ID- 1 antigenic in vivo. These data corroborate our observation 
that multiple forms of ID- 1 are expressed in vitro and in vivo, but 
only certain modified forms bind ACPAs (Figure 4A).
DISCUSSION
As a nuclear protein that alters the activity of many transcription 
factors, ID- 1 appears to affect multiple cellular properties includ-
ing proinflammatory cytokine expression. This would place ID- 1 
in a strategic position to regulate chronic inflammatory responses 
directly by inhibition of cytokine production at the transcriptional 
level. Such regulatory activity could profoundly influence the sever-
ity and progression of inflammatory outcomes in chronic diseases 
including RA. There is mounting evidence that permanently altered 
FLS function is the result of somatic mutations in key genes that 
Figure 6. Detection of anti–citrullinated protein antibodies (ACPAs) to cit–ID- 1 RA samples. A, RA SF, RA sera, and normal (NL) sera were 
assayed for autoantibodies to cit–ID- 1 by immunodot blotting. ACPA reactivity with cit–ID- 1, but not native ID- 1, was found in RA SF and peripheral 
blood (PB), but not in normal PB. Human IgG (1 μg/ml) was used as a control and showed no reactivity. Additionally, ACPAs from RA PB did not 
bind when cit–ID- 1 was boiled (denatured). Control dots showed no significant evidence of ACPAs or antibody binding reactivity in RA SF, RA PB, 
or normal PB. B, Analysis of immunodot blots via densitometry showed higher reactivity with cit–ID- 1 than noncit–ID- 1 in RA PB (n = 30 samples 
from 10 patients) and in RA SF (n = 18 samples from 6 patients), but not in normal PB (n = 12 samples from 4 patients). Bars show the mean ± 
SEM. Dotted line represents the cutoff value used to determine positive reactivity (red dots) in experimental samples. Values were derived from 
the highest white point in healthy control  samples. * = P < 0.05; *** = P < 0.001. C, Analysis of the roles of individual citrulline residues in ACPA 
reactivity of in vitro citrullinated rhID- 1 is shown. Arginines R33, R52, and R121 were critically necessary for ACPA reactivity. C denotes citrullines; 
# denotes native citrullines from the production of rhID- 1 in HEK 293 cells. BSA = bovine serum albumin (see Figure 3 for other definitions). Color 
figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40886/abstract.
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regulate the FLS cell cycle, proliferation, and apoptosis (11,12). It 
has also been suggested that RA synoviocytes have characteristics 
similar to those of tumor cells, as a number of oncogenes involved 
in cell cycle regulation—or those that act as transcription factors, 
such as c- Fos, c-ras, c-raf, c-myc, and c-myb—are expressed at 
high levels in RA FLS (12). We explored the possibility that another 
nuclear regulatory protein, namely ID- 1, plays a central role in RA 
pathogenesis, independent of tumor necrosis factor, both by reg-
ulating cytokine secretion and as an inflammatory protein that can 
undergo posttranslational modifications.
We successfully transfected primary RA FLS with a plasmid 
containing a CRISPR/Cas9 construct, demonstrated successful 
ID- 1 gene targeting using a TIDE algorithm and output analy-
sis (6), and confirmed these findings by FACS and Western blot 
analysis. We found substantial increases in IL- 6 (30- fold) and 
IL- 8 (50- fold) but not in ENA- 78/CXCL5 in supernatants from 
transfected FLS, compared to sham- transfected control FLS. 
Using a cell imaging system, we also found that FLS deleted of 
ID- 1 showed a >20% sustained reduction in proliferation. This 
may be due in part to elevated production of IL- 6, a cytokine 
known to inhibit fibroblast proliferation (13). More likely, a perma-
nent mutation in an important nuclear regulatory protein that is 
critical for cell proliferation may have altered the FLS population 
into a phenotype capable of elevated proinflammatory cytokine 
secretion. Notably, it has been shown that ID- 1 antisense RNA 
prevents early- passage fibroblasts from entering the S phase of 
the cell cycle (14). Firestein et  al proposed a model suggest-
ing a duality of FLS populations labeled “passive responders” 
and “transformed aggressors” (12), which arose partly from the 
combination of a highly inflamed environment in the RA joint and 
somatic mutations. Thus, both the data from the current study 
and previously reported findings suggest that FLS proliferation 
and heightened FLS secretion of IL- 6 represent distinct stages 
of the contributions of FLS to the pathogenesis of RA. Moreover, 
the current findings indicate that ID- 1 can mediate transition of 
FLS between these two important pathogenic phases.
Analysis of clinical specimens revealed that soluble ID- 1 is 
present and up- regulated in the serum of RA patients and shows 
a significant positive correlation with a number of disease parame-
ters including ESR, CRP level, MMP- 3 level, SDAI, CDAI, DAS28- 
CRP, and DAS28- ESR. This indicates that circulating serum ID- 1 
levels could be a potential biomarker for RA severity. Additionally, 
because serum ID- 1 concentration does not correlate with RF 
titer, it is possible to identify patients with RF- negative RA whose 
disease will be severe, by measurement of elevated ID- 1. Further-
more, after 12 weeks of infliximab, serum levels of ID- 1 showed 
significant reductions. We found that 24 of 27 patients responded 
to infliximab (based on the SDAI) and that reduction in the level of 
ID- 1 significantly correlated with reduction in disease activity in the 
responders. Because of the elevated circulating concentrations of 
ID- 1, we surmised that citrullinated forms of ID- 1 could be pres-
ent and immunogenic in RA patients, as autoantibodies to citrul-
linated proteins are well- known disease- associated phenomena 
in RA (15–19).
ACPAs are implicated in RA pathogenesis in synergy with 
smoking, an environmental risk factor for RA, and the shared 
epitope major histocompatibility complex allele (20). However, 
the full range of citrullinated autoantigens in RA is not yet defined. 
We showed that ID- 1 can be citrullinated in vitro. Moreover, by 
depleting ID- 1 from RA SFs we reduced the total amount of cit-
rullinated proteins detected by as much as 64% (mean 33%) as 
measured by cit- ELISA. We also found, by immunoblotting, that 
a subset of RA patients had high- titer autoantibodies to cit–ID- 1. 
Therefore, cit–ID- 1 in RA SF may account for a significant portion 
of citrullinated proteins that are the targets of the ACPA response 
in some RA patients.
Next, we performed immunodot blotting with RA and nor-
mal PB sera, as well as RA SF, against various citrullinated and 
noncitrullinated proteins. We were able to confirm the presence 
of ACPAs to cit–ID- 1 in both RA sera and SF but not in the PB 
from healthy individuals, which supports our hypothesis that 
citrullination of ID- 1 increases its autoantigenicity in RA. Experi-
ments using immunodot blotting for ID- 1 and cit–ID- 1 revealed 
that antibodies to cit–ID- 1 can be detected in RA sera and SF. 
In SF, the presence of large amounts of cit–ID- 1 could sequester 
anti–cit–ID- 1 in immune complexes, which could then incorpo-
rate RF and therefore be undetectable by the cit- ELISAs. Such 
mechanisms could account for the relatively low frequency of 
positivity for anti–cit–ID- 1 in SF samples.
Various citrullinated forms of ID- 1 may function differently as 
agonists or autoantigens, complicating the analysis of cit–ID- 1 
activity. This is because citrullination reactions with the PAD 
enzyme are notoriously inconsistent, resulting in differences in the 
number and patterns of arginines that are converted to citrullines. 
These inconsistencies make it difficult to determine the extent 
to which citrullination of ID- 1 leads to alterations in its activity. 
Indeed, we have found that the number and locations of arginines 
citrullinated in ID- 1 can change by simply altering the source of 
the PAD enzyme used in the reaction mix. Moreover, many of 
the mechanistic roles of ACPAs remain unknown. Notably, Schett 
et al reported that autoantibody to citrullinated vimentin directly 
induces bone loss, providing a mechanism for osteopenia in 
early or preclinical RA (21,22). In the case of the chemokine IL- 8/
CXCL8, only 1 of 3 arginines was citrullinated, yet this resulted 
in alteration of function (23). Another example in which citrullina-
tion of a single arginine by these methods resulted in functional 
changes occurred in stromal cell–derived factor 1 CXCL12 (24).
We found that some forms of cit–ID- 1 can be highly reactive 
with ACPAs formed in RA but that less deiminated forms do not 
retain autoantigenicity. It appears that the degree of citrullina-
tion of ID- 1 may alter the folding pattern and immune properties 
of ID- 1, leading to autoantigenicity. We have previously inves-
tigated the autoantigenicity of citrullinated ENA- 78/CXCL5, 
which is also highly up- regulated in RA (7). Similar to cit–ID- 1, 
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citrullination of ENA- 78/CXCL5 at arginine R48 enabled binding 
to ACPA in RA sera and SF in our assays. Furthermore, we 
previously showed that citrullination of ENA- 78/CXCL5 induced 
a functional change in the protein from a neutrophil chemoat-
tractant to a monocyte chemoattractant (7). Since citrullination 
of a protein with only 2 arginines, such as ENA- 78/CXCL5, can 
cause a profound increase in autoantigenicity and change in 
function, the impact citrullination can have on ID- 1, which con-
tains 10 arginines, could be very substantial.
Through detailed LC-MS/MS analysis, we observed conver-
sions of ID- 1 in all but 1 arginine at R103, perhaps explained by 
structural unavailability or PAD preference for certain arginines. As 
an example, the annotated fragmentation spectrum presented in 
Figure 5 shows the ions corresponding to the partial sequence of 
ID- 1 around arginine 121. These ions show the neutral loss of iso-
cyanic acid resulting from the fragmentation of the ureido group in 
citrullines, which is a marker for citrullination, confirming the modi-
fication of ID- 1. Through a series of citrullination reactions followed 
by LC-MS/MS, we identified that the modifications at arginines 
R33, R52, and R121 in cit–ID- 1 can bind to and perhaps induce 
ACPAs. However, small peptides spanning these regions were not 
reactive with RA serum, and boiling cit–ID- 1 before immunodot 
blot assays negated binding by RA sera. Overall, the data is most 
consistent with a model that involves recognition by ACPA of con-
formational, but not linear, autoantigen epitopes on cit–ID- 1.
We previously reported that ID- 1 is secreted by inflamma-
tory FLS and is an angiogenic mediator (1,2). It is possible that 
free ID- 1 is citrullinated either in FLS and/or extracellularly in 
the inflamed RA joint to render it autoantigenic in RA tissues. 
We demonstrated a potential role of ID- 1 in transforming FLS 
into a pathogenic phenotype and identified cit–ID- 1 as a novel 
autoantigen candidate in RA. Further investigation is needed to 
determine whether and how citrullination of ID- 1 may alter its 
functions. Potentially, ID- 1, cit–ID- 1, and/or ACPAs to cit–ID- 1 
may serve as promising therapeutic targets or biomarkers in RA.
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